CTCF RNA Interactome Oligonucleotide Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively modulate the expression of genes regulated by zinc-finger protein CCCTC-binding factor (CTCF), particularly in the context of inactive X chromosomes associated with X-linked diseases, where precise control of gene activation and repression is needed to address conditions like Rett Syndrome and muscular dystrophy.
Innovation Solution
Administration of inhibitory oligonucleotides targeting specific CTCF binding sites on interacting RNAs to modulate gene expression, using CLIP-seq and ChIP-seq data to identify effective binding sites and sequences for therapeutic intervention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If inhibitory oligonucleotides are administered to block CTCF binding sites, then gene expression can be selectively modulated, but the complexity of identifying effective binding sites and sequences increases
Solution Approach 1:
The patent employs CLIP-seq and ChIP-seq technologies as intermediary methods to bridge the gap between CTCF protein and its binding sites on RNAs and chromatin. These sequencing-based intermediaries systematically identify effective binding sites, converting an otherwise complex and trial-and-error process into a data-driven approach that reveals precise oligonucleotide targeting sequences for reliable gene expression modulation.
2Manufacturing precision
If current methods are used to modulate gene expression, then general gene regulation is possible, but precise control of genes on inactive X chromosomes is not achieved
Solution Approach 1:
The patent applies local quality by designing oligonucleotides that specifically target CTCF binding sites located exclusively on the inactive X chromosome (Xi). Rather than applying general gene regulation methods uniformly across all chromosomes, the invention focuses precision on Xi-specific CTCF-RNA interactions, enabling selective reactivation of X-linked genes on the inactive chromosome while leaving other genomic regions unaffected.
3Reliability
If CTCF binding is blocked to reactivate genes, then functional alleles can be expressed, but escapee genes may also be inappropriately downregulated
Solution Approach 1:
The patent segments the genome into functionally distinct regions by identifying and targeting specific CTCF binding sites on the inactive X chromosome. Through CLIP-seq and ChIP-seq analysis, the invention divides Xi into domains with active CTCF-RNA interactions versus those without, allowing oligonucleotides to be designed for precise localization. This segmentation enables selective reactivation of disease-causing gene silencing while sparing escapee genes that do not depend on targeted CTCF sites for their expression regulation.
Data Source
AI summary
This invention relates to methods and compositions for selectively reactivating or downregulating certain genes, e.g., genes regulated by zinc-finger protein CCCTC-binding factor (CTCF) on autosomes (e.g., imprinted genes, tumor suppressors, cancer) and the inactive X chromosome (Xi), e.g., genes associated with X-linked diseases, e.g., Rett Syndrome, Factor VIII or IX deficiency, Fragile X Syndrome, Duchenne muscular dystrophy, and PNH, in heterozygous females carrying a mutated allele, in addition to a functional wildtype or hypomorphic allele.